1 / 0

Amy D. Rix , Interim CEO, Founder

Inc. Amy D. Rix , Interim CEO, Founder. Stop the Bleed with… NO se BLEED …. Social/Public Issues…. Problems that can be associated with frequent nosebleeds: Embarrassing especially when out in public Loss of dignity Loss of clothes Having to stop what you are doing

matt
Télécharger la présentation

Amy D. Rix , Interim CEO, Founder

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inc. Amy D. Rix, Interim CEO, Founder Stop the Bleed with… NOseBLEED…
  2. Social/Public Issues… Problems that can be associated with frequent nosebleeds: Embarrassing especially when out in public Loss of dignity Loss of clothes Having to stop what you are doing Loss of time in a game (sports)
  3. Solution: Stop the bleed with… NOseBLEEDTM Benefits of NOseBLEED Is non-invasive to the nose Does not restrict normal breathing Stops nosebleeds in ~1-2 minutes Product is digestible Technology Technology Technology Technology Technology
  4. Sizable Need 2003 Study – 440 million total US nosebleeds per year Benninger and Marple - medical study (published/peer reviewed) 2008 Market Research Study- 700 million recurrent (more than 1 per month) nosebleeds per year Leading online survey company Market Market
  5. Business Model/Exit Contract Manufacturing Joint-venture distributors Cardinal Health McKesson Direct sales model Breathe Right Strips (CNS Inc.) DURABOND (Closure Medical Corp.) Partner and Exit Options CPC Licensing/Acquisition Options Johnson & Johnson (Closure Medical Corp., DURABOND) GSK Medical Supply Licensing/Acquisition Options McKesson Cardinal Health Business Business
  6. Financial Return Financials
  7. Value Creation Seed Round Milestones: Regulatory opinions - Prototypes – Material selection – Market research – Segment strategy - FDA approval – Ongoing Manufacturing partner(s) – Ongoing Sterilization process – Ongoing ~$350K Series A Milestones: $100 million revenue Cash flow positive Partner agreement and exit IP Continuation $2.5 Million Financials Milestones
More Related